Clinical Research Institute of Michigan – Shores Rheumatology
Main: 586-598-3329
Study Coordinator: Amelia Laurence 586-598-3329 X 201
Study Coordinator: Latrece Keaton 586-598-3329 X 202
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: CVAY736A22301
- Drug: ianalumab
- Sponsor: Novartis
- Description: A Randomized, Double-blind, Placebo-controlled, 2-arm Multicenter Phase III Study to Assess the Efficacy and Safety of Ianalumab in Participants With Sjogren’s Disease With High Symptom Burden (THALASSA)